Brown Advisory Inc. increased its position in Cambrex Co. (NYSE:CBM) by 1,638.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 161,577 shares of the biotechnology company’s stock after buying an additional 152,284 shares during the period. Brown Advisory Inc. owned 0.49% of Cambrex worth $8,888,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of CBM. Creative Planning grew its stake in shares of Cambrex by 162.6% in the 2nd quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 1,093 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of Cambrex by 9.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 150 shares during the period. Aperio Group LLC grew its stake in shares of Cambrex by 10.3% in the 2nd quarter. Aperio Group LLC now owns 10,528 shares of the biotechnology company’s stock valued at $629,000 after buying an additional 986 shares during the period. Municipal Employees Retirement System of Michigan grew its stake in shares of Cambrex by 7.5% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 9,760 shares of the biotechnology company’s stock valued at $583,000 after buying an additional 680 shares during the period. Finally, NGAM Advisors L.P. grew its stake in shares of Cambrex by 2.4% in the 2nd quarter. NGAM Advisors L.P. now owns 19,452 shares of the biotechnology company’s stock valued at $1,162,000 after buying an additional 463 shares during the period.

Several analysts have recently commented on CBM shares. BidaskClub downgraded Cambrex from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. ValuEngine downgraded Cambrex from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Craig Hallum restated a “buy” rating and issued a $60.00 target price (down from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. Cambrex presently has a consensus rating of “Hold” and a consensus price target of $62.33.

Shares of Cambrex Co. (NYSE:CBM) opened at $47.10 on Tuesday. The company has a market capitalization of $1,540.00, a PE ratio of 15.20, a PEG ratio of 1.08 and a beta of 2.26. Cambrex Co. has a 12 month low of $42.55 and a 12 month high of $62.95.

Cambrex (NYSE:CBM) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.08. The business had revenue of $112.60 million during the quarter, compared to the consensus estimate of $108.44 million. Cambrex had a return on equity of 23.42% and a net margin of 18.79%. The company’s quarterly revenue was up 13.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.47 EPS. equities research analysts forecast that Cambrex Co. will post 2.97 EPS for the current year.

In other Cambrex news, CEO Steven M. Klosk sold 4,000 shares of Cambrex stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $54.96, for a total transaction of $219,840.00. Following the completion of the transaction, the chief executive officer now owns 87,328 shares in the company, valued at approximately $4,799,546.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.48% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “Cambrex Co. (CBM) Shares Bought by Brown Advisory Inc.” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://theolympiareport.com/2017/12/05/cambrex-co-cbm-shares-bought-by-brown-advisory-inc.html.

Cambrex Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.